Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both by Langenmayer, Irmgard et al.
17S294 
Oktober 1994 
ISSN 0378-584 X 
I994:l7(suppl 2) :I -XXVI + I-174 
ONKOLOGIE 
• International Journal for Cancer Research and Treatment 
Supplement 2 
zu Band 17 
Oktober 1994 
Gemeinsame Jahrestagung der 
Deutschen und der 
Österreichischen Gesellschaft 
für Hämatologie und Onkologie 
Wien, 9.-12. Oktober 1994 
Abstracts 
Gemeinsame Jahrestagung der 
Deutschen und der 
Österreichischen Gesellschaft 
für Hämatologie und Onkologie 
Wien, 9.-12. Oktober 1994 
Abstracts 
Contents 
III Leitung und Organisation 
V-XV Author Index 
XVII-XXVI Subject Index 
1-172 Abstracts No. 1-686 
KARGER 
350 
ENGRAFTMENT OF PATIENTS WITH LYMPHOID MALIGNANCIES 
TRANSPLANTED WITH AUTOLOGOUS BONE MARROW, 
PERIPHERAL BLOOD STEM C E L L S OR BOTH 
I. Langenmaver. C. Weaver, C D . Buckner, K. Lilleby, F. R. 
Appelbaum, Κ. Longin, S . Rowley, R. Storb, J . Singer, W. 
Bensinger. Medizinische Klinik Innenstadt, Ludwig-Maximilians-
University Ziemssenstr. 1 80336 Munich and Fred Hutchinson 
Cancer Research Center 1124 Columbia Street, Seattle, 
Washington 98104 
46 patients with lymphoid malignancies receiving autologous 
transplants using three different sources of hematopoietic stem 
cells were compared for engraftment parameters. 13 patients 
received autologous marrow with posttransplant growth factors 
(group 1). During the same time 14 patients were transplanted with 
autologous marrow plus recombinant granulocyte colony 
stimulating factor (rhG-CSF) mobilized peripheral blood stem cells 
(PBSC) and posttransplant growth factors (group 2). 19 patients 
received rhG-CSF mobilized PBSC and posttransplant growth 
factors (group 3). All PBSC were collected after G - C S F mobilization 
(16 microgram/kg/day s.q. for 6 days) without prior chemotherapy. 
A median of 3 to 4 leukapheresis yielded 5.3 and 5.8*10 6 CD 34 
+ cells/kg, resp. After high dose myeloablative chemo- or 
radiochemotherapy, the median days to recover 0.5 and 1.0*10** 
neutrophils/l were 12 vs 9 vs 9 (p=0.0003) and 13 vs 10 vs 10 days 
(p=0.0003) for group 1 vs group 2. The median day to platelet 
transfusion independence was 22 vs 11 vs 11 days (p=0.001). The 
number of units of platelets transfused dropped from 119 to 39 vs 
40 (p=0.0236). No secondary graft failures were observed. No 
apparent increase in the relapse rate was observed by the addition 
of PBSC with a follow-up of 9 to 24 months. These data 
demonstrate that G-CSF mobilized peripheral blood stem cells are 
effective in reducing the time of neutropenia, platelet recovery and 
days of antibiotics in heavily pretreated patients with lymphoid 
malignancies. PBSC alone appears to be superior to marrow alone 
and the addition of marrow unnecessary. 
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